

Amendments to the Claims

The following Listing of Claims replaces all prior versions and listings of claims in the application.

Listing of Claims

27-44. (cancelled)

45. (currently amended) A pharmaceutical composition comprising a mixture that is not a molecular dispersion of the following components:

- (1) the solid composition of claim 27, 28, 29 or 30 at least 50 wt% of particles, said particles comprising a low-solubility drug and a poloxamer, wherein at least 75 wt% of said drug is amorphous; and
- (2) a concentration-enhancing polymer[;].

~~said concentration-enhancing polymer is present in a sufficient amount such that said pharmaceutical composition, following administration to an *in vivo* or *in vitro* aqueous environment of use, provides concentration enhancement relative to a control composition consisting essentially of said solid composition.~~

46. (currently amended) The pharmaceutical composition of claim 45 wherein said concentration-enhancing polymer is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, carboxymethyl ethylcellulose, and mixtures thereof.

47-48. (cancelled)

49. (withdrawn) A process for preparing a solid composition comprising the steps

- (1) forming a solution consisting essentially of a low-solubility drug, a poloxamer, and a solvent; and
- (2) removing said solvent from said solution to form said solid composition consisting essentially of said low-solubility drug and said poloxamer, at

least a substantial portion of said drug in said composition being amorphous;

Wherein said drug has a glass transition temperature of at least 50°C.

50. (withdrawn) A process for preparing a solid composition comprising the steps

(1) forming a solution consisting essentially of a low-solubility drug, a poloxamer, and a solvent; and

(2) removing said solvent from said solution to form said solid composition consisting essentially of said low-solubility drug and said poloxamer, at least a substantial portion of said drug in said composition being amorphous;

Wherein said drug has a Log P value greater than about 6.5.

51. (withdrawn) The process of claims 49 or 50 wherein step (2) is selected from the group consisting of spray drying, spray coating, rotoevaporation, and evaporation.

52. (withdrawn) The products of the process of claims 49 or 50.

53. (new) The composition of claim 45 wherein component (1) is a solid solution of said drug homogeneously distributed throughout said poloxamer.

54. (new) The composition of claim 45 or 53 wherein said mixture is a dry physical mixture.

55. (new) The composition of claim 45 or 53 wherein said mixture is present in different regions of said composition

56. (new) The composition of claim 55 wherein said mixture is present in different layers of a multi-layer tablet.

57. (new) The composition of claim 55 wherein said mixture is present in the same environment of use after components (1) and (2) have been co-administered to said

environment of use at a time ranging from approximately the same time to within 60 minutes of each other.

58. (new) The composition of claim 45 or 53 wherein said drug has a glass-transition temperature of at least 50°C.

59. (new) The composition of claim 45 or 53 wherein said drug has a Log P value of greater than 6.5.

60. (new) The composition of claim 45 or 53 wherein said drug has a melting point of T_m in K, and wherein said drug has a glass-transition temperature of $T_{g,drug}$ in K, and wherein the ratio of said melting point to said glass transition temperature, $T_m/T_{g,drug}$, is less than 1.4.

61. (new) The composition of claim 45 or 53 wherein said ratio of said melting point to said glass-transition temperature, $T_m/T_{g,drug}$, is less than 1.35.

62. (new) The composition of claim 45 or 53 wherein said ratio of said melting point to said glass-transition temperature, $T_m/T_{g,drug}$, is less than 1.3.